Targeting mTOR in Pancreatic Ductal Adenocarcinoma
Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited, however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data has shown that inhibition of mechanistic target of rapamycin (mTOR) in spe...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00099/full |
_version_ | 1818892278072082432 |
---|---|
author | Sentia eIriana Shahzad eAhmed Jun eGong Jun eGong Alagappan Anand Annamalai Richard eTuli Andrew Eugene Hendifar |
author_facet | Sentia eIriana Shahzad eAhmed Jun eGong Jun eGong Alagappan Anand Annamalai Richard eTuli Andrew Eugene Hendifar |
author_sort | Sentia eIriana |
collection | DOAJ |
description | Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited, however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data has shown that inhibition of mechanistic target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition of tumorigenesis in vitro as well as in vivo. Early phase II studies of mono-mTOR inhibition have not shown promise. However, studies have shown that combined inhibition of multiple steps along the mTOR signaling pathway may lead to sustained responses by targeting mechanisms of tumor resistance. Coordinated inhibition of mTOR along with specific KRAS-dependent mutations in molecularly defined PDAC subpopulations may offer a viable alternative for treatment in the future. |
first_indexed | 2024-12-19T17:54:09Z |
format | Article |
id | doaj.art-273b2851cee94b2b859f415e225b12f5 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-12-19T17:54:09Z |
publishDate | 2016-04-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-273b2851cee94b2b859f415e225b12f52022-12-21T20:11:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2016-04-01610.3389/fonc.2016.00099194914Targeting mTOR in Pancreatic Ductal AdenocarcinomaSentia eIriana0Shahzad eAhmed1Jun eGong2Jun eGong3Alagappan Anand Annamalai4Richard eTuli5Andrew Eugene Hendifar6Cedars-Sinai Medical CenterCedars-Sinai Medical CenterCity of Hope National Medical CenterCedars-Sinai Medical CenterCedars-Sinai Medical CenterCedars-Sinai Medical CenterCedars-Sinai Medical CenterTreatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited, however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data has shown that inhibition of mechanistic target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition of tumorigenesis in vitro as well as in vivo. Early phase II studies of mono-mTOR inhibition have not shown promise. However, studies have shown that combined inhibition of multiple steps along the mTOR signaling pathway may lead to sustained responses by targeting mechanisms of tumor resistance. Coordinated inhibition of mTOR along with specific KRAS-dependent mutations in molecularly defined PDAC subpopulations may offer a viable alternative for treatment in the future.http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00099/fullClinical Trials as TopicpreclinicalKRASmTORPancreatic Ductal Adenocarcinoma |
spellingShingle | Sentia eIriana Shahzad eAhmed Jun eGong Jun eGong Alagappan Anand Annamalai Richard eTuli Andrew Eugene Hendifar Targeting mTOR in Pancreatic Ductal Adenocarcinoma Frontiers in Oncology Clinical Trials as Topic preclinical KRAS mTOR Pancreatic Ductal Adenocarcinoma |
title | Targeting mTOR in Pancreatic Ductal Adenocarcinoma |
title_full | Targeting mTOR in Pancreatic Ductal Adenocarcinoma |
title_fullStr | Targeting mTOR in Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Targeting mTOR in Pancreatic Ductal Adenocarcinoma |
title_short | Targeting mTOR in Pancreatic Ductal Adenocarcinoma |
title_sort | targeting mtor in pancreatic ductal adenocarcinoma |
topic | Clinical Trials as Topic preclinical KRAS mTOR Pancreatic Ductal Adenocarcinoma |
url | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00099/full |
work_keys_str_mv | AT sentiaeiriana targetingmtorinpancreaticductaladenocarcinoma AT shahzadeahmed targetingmtorinpancreaticductaladenocarcinoma AT junegong targetingmtorinpancreaticductaladenocarcinoma AT junegong targetingmtorinpancreaticductaladenocarcinoma AT alagappananandannamalai targetingmtorinpancreaticductaladenocarcinoma AT richardetuli targetingmtorinpancreaticductaladenocarcinoma AT andreweugenehendifar targetingmtorinpancreaticductaladenocarcinoma |